文献速递肝病

STELLAR试验中亚洲人与非西班牙裔白人无创纤维化检测的性能表现

Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-01-22

本研究基于STELLAR试验(评估selonsertib治疗NASH相关晚期纤维化)的筛选人群,比较非西班牙裔白人与亚洲患者中NFS、FIB-4、ELF及振动控制瞬时弹性成像肝硬度四种无创检测对晚期纤维化的判别性能。结果显示两组间各检测的AUC相似,但在40岁以下患者中NFS、FIB-4和ELF的敏感性均较低。

要点

  • 在STELLAR试验筛选人群中,白人与亚洲患者各无创检测判别晚期纤维化的AUC相似。
  • 在已发表的截断值下,两组间各检测的敏感性和特异性相似。
  • 40岁以下白人和亚洲患者中,NFS、FIB-4和ELF的敏感性均较低。

核心结论

  • 在全球III期STELLAR试验中,常规无创检测对NASH相关晚期纤维化的诊断性能可接受,且在白人与亚洲患者间相似。

研究设计与样本

  • 基于STELLAR试验(NCT03053050和NCT03053063,评估selonsertib治疗NASH相关晚期F3-F4纤维化)的筛选人群分析。
  • 基线肝活检由中心按NASH临床研究网络系统判读,并测量NFS、FIB-4、ELF及振动控制瞬时弹性成像肝硬度四种无创检测。
  • 采用受试者工作特征曲线下面积评估判别晚期纤维化的性能,采用5折交叉验证重复100次。
  • 共3207例有可评估肝组织学的筛选患者,其中白人2281例、亚洲人762例。

主要发现

  • 白人72%、亚洲人67%存在晚期纤维化。
  • 判别晚期纤维化的AUC在白人与亚洲患者中分别为:NFS 0.73与0.75,FIB-4 0.78与0.80,ELF 0.79与0.81,肝硬度0.80与0.83。
  • 在已发表的截断值下,各检测在两组间的敏感性和特异性相似。
  • 在40岁以下的白人和亚洲患者中,NFS、FIB-4和ELF的敏感性均较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The effect of race on routinely available noninvasive tests of fibrosis is incompletely understood. This study evaluated the performance of noninvasive tests among white and Asian patients in the STELLAR trials (NCT03053050 and NCT03053063), which evaluated selonsertib in patients with advanced (F3-F4) fibrosis due to nonalcoholic steatohepatitis (NASH). METHODS: Baseline liver biopsies were centrally read using the NASH Clinical Research Network system, and 4 noninvasive tests (Nonalcoholic fatty liver disease fibrosis score [NFS], Fibrosis-4 index [FIB-4], Enhanced Liver Fibrosis test [ELF], and liver stiffness by vibration-controlled transient elastography) were measured. The performance of these tests to discriminate advanced fibrosis was evaluated using areas under the receiver operating characteristics curves with 5-fold cross-validation repeated 100 times. RESULTS: Among 3207 patients screened with evaluable liver histology, 2281 were whites and 762 were Asians. Seventy-two percent of whites and 67% of Asians had advanced fibrosis. The areas under the receiver operating characteristics curves of the noninvasive tests for advanced fibrosis were similar in whites and Asians: 0.73 and 0.75 for NFS, 0.78 and 0.80 for FIB-4, 0.79 and 0.81 for ELF, and 0.80 and 0.83 for liver stiffness, respectively. At the published cutoffs, the tests had similar sensitivities and specificities in the 2 groups. However, the sensitivities of NFS, FIB-4, and ELF were low in both white and Asian patients younger than 40 years. CONCLUSIONS: In the global phase III STELLAR trials, the diagnostic performance of routinely available noninvasive tests for the detection of advanced fibrosis due to NASH was acceptable and similar between white and Asian patients.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong VW, Tak WY, Goh GBB, et al. Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. Clin Gastroenterol Hepatol. 2022. PMID: 35074532. doi:10.1016/j.cgh.2022.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。